ProfileGDS5678 / 1453340_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 50% 46% 46% 47% 44% 48% 46% 45% 44% 45% 46% 46% 46% 46% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2343250
GSM967853U87-EV human glioblastoma xenograft - Control 23.0714346
GSM967854U87-EV human glioblastoma xenograft - Control 33.0724546
GSM967855U87-EV human glioblastoma xenograft - Control 43.0393947
GSM967856U87-EV human glioblastoma xenograft - Control 52.9848544
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2422248
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1636346
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0531845
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0089744
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0341545
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.067746
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0401846
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0736446
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0703646